The disclosure provides example methods, systems and apparatus for stabilization of a rib. An example method includes: (a) accessing a medullary canal of a rib having a fracture, (b) advancing a guidewire into the medullary canal across the fracture, (c) advancing a delivery catheter containing a stent over the guidewire into the medullary canal and across the fracture, (d) retracting the delivery catheter relative to the stent, and (e) expanding the stent in the medullary canal.
The disclosure provides example methods and a non-transitory computer-readable medium that has stored thereon program instructions that upon execution by a processor, cause performance of a set of acts including: (a) receiving a digital image, where the image comprises a plurality of voxels, (b) selecting from the plurality of voxels at least one voxel corresponding to soft tissue cells, (c) expanding the selected voxels to include adjacent voxels until an endpoint voxel is identified, (d) determining whether the expanded selected voxels indicate a presence of a soft tissue body, and (e) in response to a determination that the expanded selected voxels indicate the presence of the soft tissue body, associating the digital image with a database of digital images showing soft tissue bodies.
Methods of determining a disease score of a patient diagnosed with lysosomal storage disease (LSD) are described. The disease score includes one or more of the following: (i) one or more biofluid biomarkers; (ii) one or more neurophysiological measurements; and (iii) one or more neurobehavior measurement. Also described method of treating LSD including determining the disease score and administering to the patient a therapy. The therapy includes one or more of the following: (i) enzyme replacement therapy, (ii) gene therapy; and (iii) a small molecule.
A device is disclosed herein, comprising: (a) at least three lumens, comprising a first lumen, a second lumen, and a third lumen, (b) a balloon inflation port in fluid communication with the first lumen, (c) a fluid delivery port in fluid communication with the second lumen, (d) a guidewire port in fluid communication with the third lumen, (e) a balloon in fluid communication with the first lumen, wherein the balloon has a first end and a second end, (f) one or more fluid delivery channels extending a length of the second lumen, and (g) one or more fluid delivery ducts extending from the one or more fluid delivery channels to an exterior surface of the second lumen, wherein the one or more fluid delivery ducts are defined only in a portion of the second lumen that is disposed adjacent the first end of the balloon.
A visceral double-barreled main body stent graft and methods for its use, the stent graft comprises, a main body stent graft having distal and proximal ends, the main body stent graft's length ranges from about 100-120 mm and diameter at the proximal end ranges from about 30-45 mm, first and second lumens defined at the main body stent graft's distal end, the first lumen's diameter ranges from about 18-20 mm, the second lumen's diameter ranges from about 16-18 mm, the first and second lumens have about the same length from about 50-70 mm, the first lumen is secured to the second lumen along a shared length, and the main body stent graft defines a tubular wall that is contiguous with the first and second lumens such that any fluid entering the main body must exit through one of the first or second lumens.
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
A61F 2/852 - Two or more distinct overlapping stents
A61F 2/856 - Single tubular stent with side portal passage
A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
A61F 2/954 - Instruments specially adapted for placement or removal of stents or stent-grafts for placing stents or stent-grafts in a bifurcation
A balloon catheter having an elongated catheter shaft defining a fluid drainage lumen and a balloon inflation lumen. The balloon catheter includes a fluid drainage port disposed about the distal end of the catheter shaft in fluid communication with the fluid drainage lumen, and a balloon inflation port disposed about the distal end of the catheter shaft in fluid communication with the balloon inflation lumen. A balloon portion is disposed about the distal end of the catheter shaft in fluid communication with the balloon inflation port. A release device is disposed in fluid communication with the balloon portion and the fluid drainage lumen, and includes an activating member. A tether is attached to the activating member of the release device. Tension applied to the tether activates the release device, enabling fluid flow from the balloon portion into the fluid drainage lumen and out of the body.
Disclosed herein are compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of A1AT, ANGPTL4, LRP10, GFRA1, LGALS3, CST2, DKK1, CAPC, GRP78, and GRN, wherein at least one of the antibody detection markers is selected from the group consisting of A1AT, LGALS3, and CAPC, and their use in monitoring efficacy of breast cancer therapy and breast cancer recurrence.
The present disclosure provides methods and compositions for treating or limiting development of a lysosomal storage disorder, by administering to a subject that has or is at risk of a lysosomal storage disorder thereof an amount effective of a sortilin (SORT1) inhibitor to treat or limit development of the lysosomal storage disorder.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Embodiments provided herein facilitate the monitoring and management of regular healthcare tasks for patients in a healthcare system, e.g., “nurse rounding” tasks. These embodiments include providing a button or other activator that is associated with a patient and a timer that is associated with the patient and that represents the time since a rounding task was last performed for the patient. Activation of the activator by a nurse or other healthcare provider causes the patient's timer to reset. The status of the timers for a number of patients can be provided on a display, e.g., at a nurse station, to allow nurses or other healthcare providers to know at a glance which patients are currently, or likely to soon become, in need of another rounding care visit. The activator output can also be automatically registered in order to monitor performance of rounding tasks for the patient over time.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
An apparatus and methods for use are provided, where the apparatus includes: (a) a first catheter having a proximal end and a distal end, and wherein a distal portion of the first catheter includes a first one or more outlets, (b) a first tubular housing having a proximal end and a distal end, wherein the first tubular housing is coupled to the first catheter proximal to the at least one first outlet, (c) one or more pressure sensors coupled to the distal end of the first tubular housing, and (d) a second catheter having a proximal end and a distal end, wherein a distal portion of the second catheter includes a second one or more outlets, and wherein the distal end of the second catheter is configured to be positioned substantially within one of (i) the first catheter or (ii) a second tubular housing coupled to one or more of the first catheter and the first tubular housing, when the second catheter is in a first position.
The present disclosure provides an apparatus including: (a) a frame having a first end and a second end, wherein the frame includes a plurality of struts arranged between the first end and the second end of the frame, (b) a plurality of channels disposed within the plurality of struts of the frame, (c) an infusion balloon coupled to the frame and arranged such that, in an expanded condition, the frame provides a plurality of openings that the infusion balloon is configured to expand through and extend radially outward from the frame, thereby defining a plurality of grooves, (d) a plurality of holes defined in the frame and configured to permit fluid communication between the plurality of channels and the plurality of grooves, and (e) an infusion hub arranged at the first end or the second end of the frame including a reservoir in fluid communication with the plurality of channels.
Methods of determining a disease score of a patient diagnosed with lysosomal storage disease (LSD) are described. The disease score includes one or more of the following: (i) one or more biofluid biomarkers; (ii) one or more neurophysiological measurements; and (iii) one or more neurobehavior measurement. Also described method of treating LSD including determining the disease score and administering to the patient a therapy. The therapy includes one or more of the following: (i) enzyme replacement therapy, (ii) gene therapy; and (iii) a small molecule.
Pharmacogenomic (PGx) testing provides valuable insight into patient-specific mechanisms for drug response. Limitations on the throughput of PGx testing and associated costs make it currently infeasible to test every individual, particularly in large medical enterprises such as the VA or medical centers servicing large numbers of patients simultaneously. To overcome this, a method and system is described that predicts whether a patient is likely to benefit from PGx testing. Our method permits a healthcare provider to prioritize patients for PGx testing based on which patients are identified as being most likely to benefit from the testing, and can avoid PGx testing for those patients that are likely to obtain little or no benefit from the testing, thereby saving healthcare costs.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
The present disclosure provides an apparatus including a first tubular housing including a first exit port and a second tubular housing including a second exit port. The apparatus also includes a third tubular housing coupled to at least one of the first tubular housing and the second tubular housing such that each of the first tubular housing, the second tubular housing, and the third tubular housing are fixed with respect to one another. The apparatus also includes a first catheter including a first plurality of outlets and is configured to be positioned at least partially within the first tubular housing. The apparatus also includes a second catheter including a second plurality of outlets and is configured to be positioned at least partially within the second tubular housing. The apparatus also includes a pressure transducer line positioned in the third tubular housing and a pressure transducer coupled to the pressure transducer line.
The present disclosure provides a wearable garment comprising (a) a sheath having a first end and a second, wherein the sheath defines a cavity in a wearable position, wherein the sheath has a first opening at the first end, and wherein the sheath comprises a first material, and (b) one or more relief zones coupled to the sheath, wherein the relief zones comprise a second material, wherein a pressure distribution of the second material is greater than a pressure distribution of the first material.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61F 13/06 - Bandages or dressingsAbsorbent pads specially adapted for feet or legsCorn-padsCorn-rings
The present disclosure provides a catheter (100) including a first end (102), a second end (104), and a lumen (106) extending from the first end to the second end. The catheter has a first portion (108) arranged at the first end, a second portion (110) arranged adjacent to the first portion, and a third portion (112) arranged adjacent to the second portion. The first portion of the catheter has a first cut pattern in an exterior surface of the catheter, and the second portion of the catheter has a second cut pattern in the exterior surface of the catheter that is different from the first cut pattern. The third portion of the catheter has a third cut pattern in the exterior surface of the catheter that is different from the first cut pattern and the second cut pattern.
The present disclosure provides methods and compositions for treating or limiting development of a lysosomal storage disorder, by administering to a subject that has or is at risk of a lysosomal storage disorder thereof an amount effective of a sortilin (SORT1) inhibitor to treat or limit development of the lysosomal storage disorder.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
The present disclosure provides methods and compositions for treating or limiting development of a lysosomal storage disorder, by administering to a subject that has or is at risk of a lysosomal storage disorder thereof an amount effective of a p75 neurotrophin receptor (NGFR) modulator to treat or limit development of the lysosomal storage disorder.
The present disclosure provides methods and compositions for treating or limiting development of a lysosomal storage disorder, by administering to a subject that has or is at risk of a lysosomal storage disorder thereof an amount effective of a glucagon-like peptide- 1 receptor (GLP-1R) agonist to treat or limit development of the lysosomal storage disorder.
Embodiments provided herein facilitate the monitoring and management of regular healthcare tasks for patients in a healthcare system, e.g., "nurse rounding" tasks. These embodiments include providing a button or other activator that is associated with a patient and a timer that is associated with the patient and that represents the time since a rounding task was last performed for the patient. Activation of the activator by a nurse or other healthcare provider causes the patient's timer to reset. The status of the timers for a number of patients can be provided on a display, e.g., at a nurse station, to allow nurses or other healthcare providers to know at a glance which patients are currently, or likely to soon become, in need of another rounding care visit. The activator output can also be automatically registered in order to monitor performance of rounding tasks for the patient over time.
G16H 40/00 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
22.
Three-Dimensional Cross-Linked Scaffolds Of Peripheral Blood Plasma And Their Use
The disclosure provides three-dimensional cross-linked scaffolds generated from peripheral blood plasma, and methods for making and using such scaffolds.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
24.
Three-Dimensional Cross-Linked Scaffolds of Cord Blood Plasma and Their Use
Methods and related reagents are disclosed for diagnosing cancer, prognosing cancer occurrence or recurrence, and/or monitoring cancer therapy, involving contacting a bodily fluid sample from a subject at risk of having cancer or cancer recurrence, or from a subject that has been treated for cancer wl fit (a) one or more first antibody detection marker molecules that hind to human autoantibodies against at least one tumor associated antigen (TAA); and (fa) one or more second antibody detection marker molecules that bind to human autoantibodies against at least one extractable nuclear antigen (ENA).
The present disclosure provides a device including a first segment having a first length. The first segment has a first side and a second side opposite the first side. The device also includes a second segment having a second length. The second segment has a first side and a second side opposite the first side. The first segment is directly coupled to the second segment such that the first segment extends away from the second side of the second segment. The second segment includes a slot recessed in the first side of the second segment.
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A balloon catheter having an elongated catheter shaft defining a fluid drainage lumen and a balloon inflation lumen. The balloon catheter includes a fluid drainage port disposed about the distal end of the catheter shaft in fluid communication with the fluid drainage lumen, and a balloon inflation port disposed about the distal end of the catheter shaft in fluid communication with the balloon inflation lumen. A balloon portion is disposed about the distal end of the catheter shaft in fluid communication with the balloon inflation port. A release device is disposed in fluid communication with the balloon portion and the fluid drainage lumen, and includes an activating member. A tether is attached to the activating member of the release device. Tension applied to the tether activates the release device, enabling fluid flow from the balloon portion into the fluid drainage lumen and out of the body.
The disclosure provides example methods, systems and apparatus for stabilization of a rib. An example method includes: (a) accessing a medullary canal of a rib having a fracture, (b) advancing a guidewire into the medullary canal across the fracture, (c) advancing a delivery catheter containing a stent over the guidewire into the medullary canal and across the fracture, (d) retracting the delivery catheter relative to the stent, and (e) expanding the stent in the medullary canal.
A visceral double-barreled main body stent graft and methods for its use, the stent graft comprises, a main body stent graft having distal and proximal ends, the main body stent graft's length ranges from about 100-120 mm and diameter at the proximal end ranges from about 30-45 mm, first and second lumens defined at the main body stent graft's distal end, the first lumen's diameter ranges from about 18-20 mm, the second lumen's diameter ranges from about 16-18 mm, the first and second lumens have about the same length from about 50-70 mm, the first lumen is secured to the second lumen along a shared length, and the main body stent graft defines a tubular wall that is contiguous with the first and second lumens such that any fluid entering the main body must exit through one of the first or second lumens.
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
A61F 2/852 - Two or more distinct overlapping stents
A61F 2/856 - Single tubular stent with side portal passage
A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
30.
PREDICTIVE TEST FOR WHETHER A PATIENT WILL BENEFIT FROM PHARMACOGENOMICS TESTING
Pharmacogenomic (PGx) testing provides valuable insight into patient-specific mechanisms for drug response. Limitations on the throughput of PGx testing and associated costs make it currently infeasible to test every individual, particularly in large medical enterprises such as the VA or medical centers servicing large numbers of patients simultaneously. To overcome this, a method and system is described that predicts whether a patient is likely to benefit from PGx testing. Our method permits a healthcare provider to prioritize patients for PGx testing based on which patients are identified as being most Iikely to benefit from the testing, and can avoid PGx testing for those patients that are Iikely to obtain little or no benefit from the testing, thereby saving healthcare costs.
The present disclosure provides a catheter system and methods for use that includes (a) a first catheter having a first end and a second end, where the first catheter has a first diameter, (b) a second catheter having a first end and a second end, where the second catheter has a second diameter that is less than the first diameter of the first catheter, and where the second catheter is positioned at least partially within a lumen of the first catheter and is moveable relative to the first catheter, and (c) a wire having a first end and a second end, where the first end of the wire is coupled to the second catheter.
The disclosure provides example methods and a non-transitory computer-readable medium that has stored thereon program instructions that upon execution by a processor, cause performance of a set of acts including: (a) receiving a digital image, where the image comprises a plurality of voxels, (b) selecting from the plurality of voxels at least one voxel corresponding to soft tissue cells, (c) expanding the selected voxels to include adjacent voxels until an endpoint voxel is identified, (d) determining whether the expanded selected voxels indicate a presence of a soft tissue body, and (e) in response to a determination that the expanded selected voxels indicate the presence of the soft tissue body, associating the digital image with a database of digital images showing soft tissue bodies.
A visceral double-barreled main body stent graft and methods for its use, the stent graft comprises, a main body stent graft having distal and proximal ends, the main body stent graft's length ranges from about 100-120 mm and diameter at the proximal end ranges from about 30-45 mm, first and second lumens defined at the main body stent graft's distal end, the first lumen's diameter ranges from about 18-20 mm, the second lumen's diameter ranges from about 16-18 mm, the first and second lumens have about the same length from about 50-70 mm, the first lumen is secured to the second lumen along a shared length, and the main body stent graft defines a tubular wall that is contiguous with the first and second lumens such that any fluid entering the main body must exit through one of the first or second lumens.
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
A61F 2/852 - Two or more distinct overlapping stents
A61F 2/856 - Single tubular stent with side portal passage
A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
34.
Debranching visceral stent grant and methods for use
A visceral double-barreled main body stent graft and methods for its use, the stent graft comprises, a main body stent graft having distal and proximal ends, the main body stent graft's length ranges from about 100-120 mm and diameter at the proximal end ranges from about 30-45 mm, first and second lumens defined at the main body stent graft's distal end, the first lumen's diameter ranges from about 18-20 mm, the second lumen's diameter ranges from about 16-18 mm, the first and second lumens have about the same length from about 50-70 mm, the first lumen is secured to the second lumen along a shared length, and the main body stent graft defines a tubular wall that is contiguous with the first and second lumens such that any fluid entering the main body must exit through one of the first or second lumens.
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
A61F 2/852 - Two or more distinct overlapping stents
A61F 2/856 - Single tubular stent with side portal passage
A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
The present disclosure provides a catheter (100) including a first end (102), a second end (104), and a lumen (106) extending from the first end to the second end. The catheter has a first portion (108) arranged at the first end, a second portion (110) arranged adjacent to the first portion, and a third portion (112) arranged adjacent to the second portion. The first portion of the catheter has a first cut pattern in an exterior surface of the catheter, and the second portion of the catheter has a second cut pattern in the exterior surface of the catheter that is different from the first cut pattern. The third portion of the catheter has a third cut pattern in the exterior surface of the catheter that is different from the first cut pattern and the second cut pattern.
Example stent grafts and methods for placement thereof are provided. An example stent graft may include (a) a main body stent graft defining a lumen that has a first end and a second end, (b) a diaphragm coupled to the main body stent graft, where the diaphragm defines at least three openings and (c) at least three stent graft extensions each defining a lumen, where a first end of each of the three stent graft extensions is coupled to one of the three openings.
A device is disclosed herein, comprising: (a) at least three lumens, comprising a first lumen, a second lumen, and a third lumen, (b) a balloon inflation port in fluid communication with the first lumen, (c) a fluid delivery port in fluid communication with the second lumen, (d) a guidewire port in fluid communication with the third lumen, (e) a balloon in fluid communication with the first lumen, wherein the balloon has a first end and a second end, (f) one or more fluid delivery channels extending a length of the second lumen, and (g) one or more fluid delivery ducts extending from the one or more fluid delivery channels to an exterior surface of the second lumen, wherein the one or more fluid delivery ducts are defined only in a portion of the second lumen that is disposed adjacent the first end of the balloon.
The present disclosure provides an apparatus including: (a) a frame (102) having a first end (104) and a second end (106), wherein the frame includes a plurality of struts (108) arranged between the first end and the second end of the frame, (b) a plurality of channels (110) disposed within the plurality of struts of the frame, (c) an infusion balloon (112) coupled to the frame and arranged such that, in an expanded condition, the frame provides a plurality of openings (114) that the infusion balloon is configured to expand through and extend radially outward from the frame, thereby defining a plurality of grooves (116), (d) a plurality of holes (118) defined in the frame and configured to permit fluid communication between the plurality of channels and the plurality of grooves, and (e) an infusion hub (120) arranged at the first end or the second end of the frame including a reservoir in fluid communication with the plurality of channels.
An apparatus and methods for use are provided, where the apparatus includes: (a) a first catheter having a proximal end and a distal end, and wherein a distal portion of the first catheter includes a first one or more outlets, (b) a first tubular housing having a proximal end and a distal end, wherein the first tubular housing is coupled to the first catheter proximal to the at least one first outlet, (c) one or more pressure sensors coupled to the distal end of the first tubular housing, and (d) a second catheter having a proximal end and a distal end, wherein a distal portion of the second catheter includes a second one or more outlets, and wherein the distal end of the second catheter is configured to be positioned substantially within one of (i) the first catheter or (ii) a second tubular housing coupled to one or more of the first catheter and the first tubular housing, when the second catheter is in a first position.
The disclosure provides example apparatus and methods. One example apparatus includes a first woven stent having a curved form in an expanded state. In the expanded state, at least a first portion of the first woven stent has a weave pattern arranged along an outer curvature of the first woven stent that is different than a weave pattern arranged along an inner curvature of the first woven stent. And the first woven stent is biased toward the curved form due to shape memory.
A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
A61F 2/01 - Filters implantable into blood vessels
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
41.
REAGENTS AND METHODS FOR CANCER DETECTION, PROGNOSIS, AND THERAPEUTIC MONITORING
Methods and related reagents are disclosed for diagnosing cancer, prognosing cancer occurrence or recurrence, and/or monitoring cancer therapy, involving contacting a bodily fluid sample from a subject at risk of having cancer or cancer recurrence, or from a subject that has been treated for cancer wl fit (a)one or more first antibody detection marker molecules that hind to human autoantibodies against at least one tumor associated antigen (TAA); and (fa) one or more second antibody detection marker molecules that bind to human autoantibodies against at least one extractable nuclear antigen (ENA).
The disclosure provides three-dimensional cross-linked scaffolds generated from peripheral blood plasma, and methods for making and using such scaffolds.
The present disclosure provides a device that includes a tube having a first end and a second end. The device also includes a stopper coupled to a surface of the tube adjacent to the second end of the tube. The stopper is configured to extend radially from the surface of the tube. The device also includes a first rib coupled to the surface of the tube. The device also includes a second rib coupled to the surface of the tube. The first rib and the second rib are positioned opposite one another on the surface of the tube between the first end of the tube and the stopper.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides an apparatus including a first tubular housing including a first exit port and a second tubular housing including a second exit port. The apparatus also includes a third tubular housing coupled to at least one of the first tubular housing and the second tubular housing such that each of the first tubular housing, the second tubular housing, and the third tubular housing are fixed with respect to one another. The apparatus also includes a first catheter including a first plurality of outlets and is configured to be positioned at least partially within the first tubular housing. The apparatus also includes a second catheter including a second plurality of outlets and is configured to be positioned at least partially within of the second tubular housing. The apparatus also includes a pressure transducer line positioned in the third tubular housing and a pressure transducer coupled to the pressure transducer line.
The disclosure provides example methods, systems and apparatus for stabilization of a rib. An example method includes: (a) accessing a medullary canal of a rib having a fracture, (b) advancing a guidewire into the medullary canal across the fracture, (c) advancing a delivery catheter containing a stent over the guidewire into the medullary canal and across the fracture, (d) retracting the delivery catheter relative to the stent, and (e) expanding the stent in the medullary canal.
The disclosure provides example methods and a non-transitory computer-readable medium that has stored thereon program instructions that upon execution by a processor, cause performance of a set of acts including: (a) receiving a digital image, where the image comprises a plurality of voxels, (b) selecting from the plurality of voxels at least one voxel corresponding to soft tissue cells, (c) expanding the selected voxels to include adjacent voxels until an endpoint voxel is identified, (d) determining whether the expanded selected voxels indicate a presence of a soft tissue body, and (e) in response to a determination that the expanded selected voxels indicate the presence of the soft tissue body, associating the digital image with a database of digital images showing soft tissue bodies.
The present disclosure provides a device that includes (a) a chest support, (h) a neck support, (c) a chin support, (d) a pair of upper side struts each having a first end coupled to the chin support and a second end coupled to the neck support, and (e) a pair of lower side struts each having a first end coupled to the chest support and a second end coupled to the neck support.
Disclosed herein are compositions and methods for tumor treatment involving administering to a subject having a tumor with an amount effective to limit tumor growth or metastasis of an ephrin B1 inhibitor, or a pharmaceutically acceptable salt thereof; and/or an inhibitor of tumor exosomal release, or a pharmaceutically acceptable salt thereof.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
54.
AORTIC FILTER AND FLOW DIVERTER AND METHODS FOR USE THEREOF
The disclosure provides example apparatus and methods. One example apparatus includes a first woven stent having a curved form in an expanded state. In the expanded state, at least a first portion of the first woven stent has a weave pattern arranged along an outer curvature of the first woven stent that is different than a weave pattern arranged along an inner curvature of the first woven stent. And the first woven stent is biased toward the curved form due to shape memory.
A visceral double-barreled main body stent graft and methods for its use, the stent graft comprises, a main body stent graft having distal and proximal ends, the main body stent graft's length ranges from about 100-120 mm and diameter at the proximal end ranges from about 30-45 mm, first and second lumens defined at the main body stent graft's distal end, the first lumen's diameter ranges from about 18-20 mm, the second lumen's diameter ranges from about 16-18 mm, the first and second lumens have about the same length from about 50-70 mm, the first lumen is secured to the second lumen along a shared length, and the main body stent graft defines a tubular wall that is contiguous with the first and second lumens such that any fluid entering the main body must exit through one of the first or second lumens.
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
A61F 2/856 - Single tubular stent with side portal passage
An apparatus and methods for use are provided, where the apparatus includes: (a) a filter, and (b) a frame having a first end and a second end, wherein the frame includes a first support and a second support extending between the first end and the second end, wherein at least the first support and the second support of the frame are coupled to at least a portion of a periphery of the filter, wherein the frame and the filter together define a lumen, wherein the frame has shape memory and is movable between a first position in which the lumen has a first diameter and a second position in which the lumen has a second diameter, and wherein the first diameter is smaller than the second diameter.
A drug delivery balloon apparatus is disclosed herein, comprising: (a) at least two lumens, comprising a first lumen and a second lumen, (b) a balloon inflation port in fluid communication with the first lumen, (c) a drug delivery port in fluid communication with the second lumen, (d) a guidewire port in fluid communication with the second lumen, wherein the second lumen is configured to receive both a guidewire and a drug solution, (e) an occlusion balloon, (f) a drug delivery balloon, where the occlusion balloon and the drug delivery balloon are in fluid communication with the first lumen, (g) one or more drug delivery channels extending the length of the second lumen, and (h) one or more drug delivery ducts extending from the one or more drug delivery channels to an exterior surface of the second lumen.
A balloon catheter having an elongated catheter shaft defining a fluid drainage lumen and a balloon inflation lumen. The balloon catheter includes a fluid drainage port disposed about the distal end of the catheter shaft in fluid communication with the fluid drainage lumen, and a balloon inflation port disposed about the distal end of the catheter shaft in fluid communication with the balloon inflation lumen. A balloon portion is disposed about the distal end of the catheter shaft in fluid communication with the balloon inflation port. A release device is disposed in fluid communication with the balloon portion and the fluid drainage lumen, and includes an activating member. A tether is attached to the activating member of the release device. Tension applied to the tether activates the release device, enabling fluid flow from the balloon portion into the fluid drainage lumen and out of the body.
The present disclosure provides an apparatus including a first clip configured to move between an open position and a closed position. The apparatus also includes a second clip configured to move between an open position and a closed position. The apparatus also includes an elongated connector that is semi-rigid and deformable and that has a first end and a second end. The first end of the elongated connector is coupled to the first clip, and the second end of the elongated connector is coupled to the second clip. The apparatus also includes a sensor coupled to the elongated connector between the first end and the second end.
The present disclosure provides an apparatus including a first tubular housing including a first exit port and a second tubular housing including a second exit port. The apparatus also includes a third tubular housing coupled to at least one of the first tubular housing and the second tubular housing such that each of the first tubular housing, the second tubular housing, and the third tubular housing are fixed with respect to one another. The apparatus also includes a first catheter including a first plurality of outlets and is configured to be positioned at least partially within the first tubular housing. The apparatus also includes a second catheter including a second plurality of outlets and is configured to be positioned at least partially within the second tubular housing. The apparatus also includes a pressure transducer line positioned in the third tubular housing and a pressure transducer coupled to the pressure transducer line.
The present disclosure provides a catheter tip (100) including a flexible housing (102) defining a cavity (104) extending between an expandable opening (106) arranged at a first end (108) of the catheter tip and a second end (110) of the catheter tip. The catheter tip further includes a plurality of pivotable arms (112) coupled to and extending longitudinally along the flexible housing. The plurality of pivotable arms are arranged to taper inwardly at the first end of the catheter tip toward a longitudinal axis of the flexible housing. The expandable opening is configured to increase in diameter from a first position to a second position in response to application of an external force to the second end of the flexible housing.
The present disclosure provides an apparatus (100) comprising a guide wire (102) having a non-coiled segment (104), a leading segment (106), and a first expandable segment (108) positioned between the non-coiled segment (104) and the leading segment (106). The first expandable segment (108) has a first end (114) and a second end (116) and is configured to transition between a constrained state and a deployed state. The first end (114) of the first expandable segment (108) is closer to a first end (110) of the leading segment (106) than a second end (116) of the first expandable segment (108) in the constrained state, and a second end (116) of the first expandable segment (108) is closer to the first end (110) of the leading segment (106) than the first end (114) of the first expandable segment (108) in the deployed state.
The present disclosure provides an apparatus including a catheter having a first end and a second end and defining a lumen extending from the first end to the second end. The apparatus also includes one or more openings positioned in a side wall of the catheter between the first end and the second end of the catheter. The apparatus also includes one or more coverings positioned over the one or more openings. A diverter is configured to contact a first covering of the one or more coverings to transition the first covering from a first position to a second position where the first covering projects away from a side wall of the catheter to at least partially obstruct the lumen of the catheter such that the first opening of the one or more openings is accessible via the lumen.
The present disclosure provides a catheter system including: (a) a first catheter having a first end and a second end, the first catheter defining a first lumen, (b) a second catheter having a first end and a second end, the second catheter defining a second lumen, where the first catheter is positioned at least partially within the second lumen of the second catheter, and the second catheter and the first catheter are moveable with respect to each other, and (c) a filter coupled to the first catheter, where the filter comprises an expandable frame and a semipermeable membrane coupled to the expandable frame, and where the expandable frame has shape memory and is movable from a compressed position to an expanded position in response to the second catheter being retracted relative to the first catheter and/or the first catheter being advanced relative to the second catheter.
Disclosed herein are methods for producing induced T regulatory cells (iTregs), involving contacting naive CD4+CD25- T cells and/or naive CD8+CD25- T cells in vitro with (i) a polypeptide comprising an Ig-C domain from a B7-H4 protein (also known as VTCNl, B7x or B7S 1), wherein the polypeptide is not the full B7-H4 protein and does not include the B7-H4 protein IgV domain, (ii) anti-CD3 antibodies, (iii) anti-CD28 antibodies, and (iv) interleukin-2 (IL-2), wherein the contacting occurs for a time and under conditions sufficient to cause conversion of naive CD4+CD25- T cells and/or naive CD8+CD25- T cells into iTregs.
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61P 37/00 - Drugs for immunological or allergic disorders
66.
Pararenal and thoracic arch stent graft and methods for use
Example stent grafts and methods for placement thereof are provided. An example stent graft may include (a) a main body stent graft defining a lumen that has a first end and a second end, (b) a diaphragm coupled to the main body stent graft, where the diaphragm defines at least three openings and (c) at least three stent graft extensions each defining a lumen, where a first end of each of the three stent graft extensions is coupled to one of the three openings.
Apparatus, systems and methods for use thereof are disclosed. An example apparatus includes a filter having an expandable frame and a semipermeable membrane coupled to the expandable frame. The expandable frame has a cone-shape in an expanded position. An apex of the expandable frame is arranged at the filter's first end. The expandable frame has a plurality of polygonal supports coupled together at the apex and that are radially biased outward such that in the expanded position the polygonal supports are spaced apart at a second end of the filter with the semipermeable membrane extending therebetween. The semipermeable membrane covers an area defined by the polygonal supports. A plurality of struts each have a first and second end, and the first end of each of the struts is coupled to a second end of the expandable frame. A stent is coupled to each of the second ends of the struts.
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/221 - Calculus gripping devices in the form of loops or baskets
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61F 2/01 - Filters implantable into blood vessels
68.
CATHETER WITH A SIDE PORT AND METHODS FOR USE THEREOF
The present disclosure provides a catheter comprising: (a) a first tubular structure defining a first lumen, the first tubular structure having a first end and a second end, wherein the first end of the first tubular structure comprises a first opening, and wherein the second end of the first tubular structure comprises a second opening, (b) a second tubular structure defining a second lumen, the second tubular structure having a first end and a second end, wherein the second end of the second tubular structure comprises a third opening, and (c) a fourth opening positioned in a sidewail of the second tubular structure between the first end of the second tubular structure and the second end of the second tubular staicture, wherein a first portion of the first tubular structure extends beyond the fourth opening, and wherem the second tubular structure is positioned adjacent to a second portion of the first tubular structure.
The present disclosure provides a catheter comprising: (a) a first tubular structure defining a first lumen, the first tubular structure having a first end and a second end, wherein the first end of the first tubular structure comprises a first opening, and wherein the second end of the first tubular structure comprises a second opening, (b) a second tubular structure defining a second lumen, the second tubular structure having a first end and a second end, wherein the second end of the second tubular structure comprises a third opening, and (c) a fourth opening positioned in a sidewall of the second tubular structure between the first end of the second tubular structure and the second end of the second tubular structure, wherein a first portion of the first tubular structure extends beyond the fourth opening, and wherein the second tubular structure is positioned adjacent to a second portion of the first tubular structure.
The present invention provides formulations comprising polymers and therapeutics and methods for their manufacture. The present invention also provides medical devices coated with such formulations and methods for their manufacture. The drug-loaded polymer formulations, solutions, and films tailor the drug release characteristics for medical devices.
The present disclosure provides an apparatus including: (a) a frame (102) having a first end (104) and a second end (106), wherein the frame includes a plurality of struts (108) arranged between the first end and the second end of the frame, (b) a plurality of channels (110) disposed within the plurality of struts of the frame, (c) an infusion balloon (112) coupled to the frame and arranged such that, in an expanded condition, the frame provides a plurality of openings (114) that the infusion balloon is configured to expand through and extend radially outward from the frame, thereby defining a plurality of grooves (116), (d) a plurality of holes (118) defined in the frame and configured to permit fluid communication between the plurality of channels and the plurality of grooves, and (e) an infusion hub (120) arranged at the first end or the second end of the frame including a reservoir in fluid communication with the plurality of channels.
Disclosed herein are compositions and methods for tumor treatment involving administering to a subject having a tumor with an amount effective to limit tumor growth or metastasis of an ephrin Bl inhibitor, or a pharmaceutically acceptable salt thereof; and/or an inhibitor of tumor exosomal release, or a pharmaceutically acceptable salt thereof
The present disclosure provides a device that includes: (a) a tube having a first end and a second end, (b) a stopper coupled to a surface of the tube adjacent to the second end of the tube, where the stopper is configured to extend radially from the surface of the tube, (c) a first rib coupled to the surface of the tube, and (d) a second rib coupled to the surface of the tube, where the first rib and the second rib are positioned opposite one another on the surface of the tube between the first end of the tube and the stopper.
The present disclosure provides a catheter including a first tubular structure defining a first lumen, the first tubular structure having a first end and a second end. The catheter may also include a second tubular structure defining a second lumen, the second tubular structure having a first end and a second end. The catheter may also include an aperture between the first tubular structure and the second tubular structure. The aperture is located at the first end of the second tubular structure. A first portion of the first tubular structure extends beyond the aperture, and the second tubular structure is positioned adjacent to a second portion of the first tubular structure.
A catheter (100) including a first tubular structure (102) defining a first lumen (104), the first tubular structure having a first end (106) and a second end (108). The catheter may also include a second tubular structure (110) defining a second lumen (112), the second tubular structure having a first end (114) and a second end (116). The catheter may also include an aperture (118) between the first tubular structure and the second tubular structure. The aperture is located at the first end of the second tubular structure. A first portion of the first tubular structure extends beyond the aperture, and the second tubular structure is positioned adjacent to a second portion of the first tubular structure.
The present disclosure provides a catheter system and methods for use that includes (a) a first catheter having a first end and a second end, where the first catheter has a first diameter, (b) a second catheter having a first end and a second end, where the second catheter has a second diameter that is less than the first diameter of the first catheter, and where the second catheter is positioned at least partially within a lumen of the first catheter and is moveable relative to the first catheter, and (c) a wire having a first end and a second end, where the first end of the wire is coupled to the second catheter.
The present disclosure provides a catheter system and methods for use that includes (a) a first catheter having a first end and a second end, where the first catheter has a first diameter, (b) a second catheter having a first end and a second end, where the second catheter has a second diameter that is less than the first diameter of the first catheter, and where the second catheter is positioned at least partially within a lumen of the first catheter and is moveable relative to the first catheter, and (c) a wire having a first end and a second end, where the first end of the wire is coupled to the second catheter.
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
new technology commercialization services, namely, assistance in business management and product commercialization development of new technology for others in the field of medicine licensing of intellectual property
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
New technology commercialization services, namely, assistance in business management and product commercialization Development of new technology for others in the field of medicine Licensing of intellectual property
The present disclosure provides an apparatus that includes a first catheter having a proximal end and a distal end. The apparatus also includes a first tubular housing having a proximal end and a distal end. The first tubular housing is coupled to the first catheter proximal to at least one first outlet. The apparatus also includes one or more pressure sensors coupled to the distal end of the first tubular housing. The apparatus also includes a second catheter having a proximal end and a distal end. The distal end of the second catheter is configured to be positioned substantially within a second tubular housing coupled to one or more of the first catheter and the first tubular housing, when the second catheter is in a first position.
The present disclosure provides a catheter tip comprising a cavity extending between an expandable opening arranged at a first end of the catheter tip and a second end of the catheter tip, wherein the expandable opening is configured to increase in diameter from a first position to a second position in response to application of an external force to the second end of the catheter tip.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Retail store services featuring health care equipment,
health care, wellness, fitness and spa products and
supplies, and retail pharmacy services. Medical educational services, namely, providing classes,
seminars and workshops for the general public in the field
of health and dissemination of related educational
materials; providing classes, seminars and training for
medical students, residents and other health care
professionals, and providing continuing medical education
for health care professionals. Medical and health care services, namely, hospitals,
inpatient and outpatient services, clinical services,
rehabilitation services, physician services, medical testing
services, nursing care services; health care in the nature
of a health maintenance organization; home health care
services; long term care services; medical diagnostic
services; rental of medical equipment; recording,
collecting, sharing, and reviewing, patient-specific health
care information via a website.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Retail store services featuring health care equipment,
health care, wellness, fitness and spa products and
supplies; and retail pharmacy services. Medical educational services, namely providing classes,
seminars and workshops for the general public in the field
of health and dissemination of related educational
materials; providing classes, seminars and training for
medical students, residents and other health care
professionals, and providing continuing medical education
for health care professionals; fitness center services. Medical and health care services, namely, hospitals,
inpatient and outpatient services, clinical services,
rehabilitation services, physician services, medical testing
services, nursing care services; health care in the nature
of a health maintenance organization; home health care
services; long term care services; medical diagnostic
services; rental of medical equipment; recording,
collecting, sharing, and reviewing, patient-specific health
care information via a website.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Retail store services featuring health care equipment,
health care, wellness, fitness and spa products and
supplies, and retail pharmacy services. Medical educational services, namely, providing classes,
seminars and workshops for the general public in the field
of health and dissemination of related educational
materials; providing classes, seminars and training for
medical students, residents and other health care
professionals, and providing continuing medical education
for health care professionals. Medical and health care services, namely, hospitals,
inpatient and outpatient services, clinical services,
rehabilitation services, physician services, medical testing
services, nursing care services; health care in the nature
of a health maintenance organization; home health care
services; long term care services; medical diagnostic
services; rental of medical equipment; recording,
collecting, sharing, and reviewing, patient-specific health
care information via a website.
The present invention provides formulations comprising polymers and therapeutics and methods for their manufacture. The present invention also provides medical devices coated with such formulations and methods for their manufacture. The drug-loaded polymer formulations, solutions, and films tailor the drug release characteristics for medical devices.
The present disclosure provides a wound closure device that includes (a) a biocompatible material configured to be brought into abutment with a tissue surface, and (b) a plurality of fixation components connected to and extending through the biocompatible material, where at least one of the plurality of fixation components is configured to allow a suture to be connected to and extend through the at least one fixation component.
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
The present disclosure provides a deployment device that includes (a) an elongate shaft having a first end and a second end, (b) a grasping assembly coupled to the first end of the elongate shaft, where the grasping assembly includes a first jaw and a second jaw rotatable with respect to the elongate shaft, where the grasping assembly is configured to accept a wound closure device between the first jaw and the second jaw, where the wound closure device comprises at least two fixation components connected to and extending therethrough, where each of the first jaw and the second jaw include at least one coupling element configured to be removably coupled to a respective fixation component when the wound closure device is coupled to the grasping assembly, and (c) an actuator coupled to the second end of the elongate shaft, where the actuator is configured to move the grasping assembly between an open position and a closed position.
A drug delivery balloon apparatus is disclosed herein, comprising: (a) at least two lumens, comprising a first lumen and a second lumen, (b) a balloon inflation port in fluid communication with the first lumen, (c) a drug delivery port in fluid communication with the second lumen, (d) a guidewire port in fluid communication with the second lumen, wherein the second lumen is configured to receive both a guidewire and a drug solution, (e) an occlusion balloon, (f) a drug delivery balloon, where the occlusion balloon and the drug delivery balloon are in fluid communication with the first lumen, (g) one or more drug delivery channels extending the length of the second lumen, and (h) one or more drug delivery ducts extending from the one or more drug delivery channels to an exterior surface of the second lumen.
Disclosed herein are compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of A1AT, ANGPTL4, LRPIO, GFRAl, LGALS3, CST2, DKKl, CAPC, GRP78, and GRN, wherein at least one of the antibody detection markers is selected from the group consisting of A 1 AT, LGALS3, and CAPC, and their use in monitoring efficacy of breast cancer therapy and breast cancer recurrence.
THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (USA)
SANFORD HEALTH (USA)
Inventor
Pyeon, Dohun
Lee, John
Abstract
DNA methylation profiles predictive of head and neck squamous cell carcinoma (HNSCC) patient prognosis, as well as therapeutic protein and adoptive cell compositions useful in the treatment of HNSCC.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present disclosure provides a wearable garment comprising (a) a sheath having a first end and a second, wherein the sheath defines a cavity in a wearable position, wherein the sheath has a first opening at the first end, and wherein the sheath comprises a first material, and (b) one or more relief zones coupled to the sheath, wherein the relief zones comprise a second material, wherein a pressure distribution of the second material is greater than a pressure distribution of the first material.
The present disclosure provides a stent graft having a lumen, the stent graft comprising (a) a first side and a second side opposite the first side, wherein the first side and the second side of the stent graft extend between a first end and a second end of the stent graft, and (b) a longitudinal support extending between the first end and the second end of the stent graft and coupled to one of the first side or the second side of the stent graft, and wherein, in an expanded condition, the stent graft has a radius of curvature and has a length of the first side that is longer than a length of the second side.
The present disclosure provides a wearable garment comprising (a) a sheath having a first end and a second, wherein the sheath defines a cavity in a wearable position, wherein the sheath has a first opening at the first end, and wherein the sheath comprises a first material, and (b) one or more relief zones coupled to the sheath, wherein the relief zones comprise a second material, wherein a pressure distribution of the second material is greater than a pressure distribution of the first material.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61F 13/06 - Bandages or dressingsAbsorbent pads specially adapted for feet or legsCorn-padsCorn-rings
94.
SELF-EXPANDING BRIDGING STENT WITH ANCHORING PROJECTIONS AND METHODS FOR USE
The present disclosure provides a stent graft comprising (a) a self-expandable stent structure having a first end and a second end, wherein the self-expandable stent structure defines a lumen, (b) at least one restraint configured to be coupled to an exterior surface of the stent graft in a compressed condition, and wherein the at least one restraint is configured to be broken to permit the stent graft to transition to an expanded condition, and (c) a first plurality of anchoring projections coupled to the exterior surface of the stent graft adjacent to the first end of the self-expandable stent-structure.
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
95.
BRIDGING STENT GRAFT WITH COMBINATION BALLOON EXPANDABLE AND SELF-EXPANDABLE STENTS AND METHODS FOR USE
The present disclosure provides a stent graft (100) defining a lumen (102) having a first end (104) and a second end (106), the stent graft comprising (a) a first portion (108) at the first end of the stent graft having a first diameter (D1) and a first length (L1), wherein a first stent structure of the first portion is balloon-expandable, (b) a second portion (112) of the stent graft having a second diameter (D2) and a second length (L1), wherein a second stent structure of the second portion is self-expanding, (c) a breakable restraint (116) configured to be coupled to the second portion in a pre-deployment state and decoupled from the second portion in a deployed state, and (d) a third portion (120) at the second end of the stent graft has a third diameter (D3) and a third length (L3), wherein a third stent structure of the third portion is balloon-expandable.
The present disclosure provides a catheter tip (100) comprising a flexible housing (102) comprising a cavity (104) extending between an expandable opening (106) arranged at a first end (108) of the catheter tip and a second end (110) of the catheter tip, wherein the expandable opening is configured to increase in diameter from a first position to a second position in response to application of an external force to the second end of the flexible housing.
The present disclosure provides a stent graft (100) comprising (a) a self-expandable stent structure (102) and a graft covering (104) positioned over the self-expandable stent structure, the self-expandable stent structure having a first end (106) and a second end (108). wherein the self-expandable stent structure defines a lumen (110), and (b) at least one annular channel defined by at least one of the self-expandable stent structure and the graft covering and extending radially outward from the self-expandable stent structure or at least one annular protrusion (116) defined by at least one of the self-expandable stent structure and the graft covering and extending radially inward from the self-expandable stent structure.
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
A61F 2/954 - Instruments specially adapted for placement or removal of stents or stent-grafts for placing stents or stent-grafts in a bifurcation
98.
Polynucleotides for treating oncogenic viral polypeptide positive tumors
This document relates to polynucleotides encoding antigenic polypeptides to induce an immune response to oncogenic viral polypeptides. Also provided are compositions comprising polynucleotides encoding antigenic polypeptides, and methods of use. In the provided methods, the virus can be a human papilloma virus. In some embodiments, a method for killing a cell expressing a first oncogenic viral polypeptide in a subject is provided. The method includes administering to the subject a composition in an amount sufficient to initiate an immune response against the first oncogenic viral peptide, where the composition comprises a pharmaceutically acceptable carrier and a polynucleotide provided herein and the immune response is effective to cause a cytotoxic effect in the cell. In some embodiments, the polynucleotide includes a second nucleotide sequence encoding a second antigenic polypeptide. The first oncogenic viral polypeptide can be E6 and the second oncogenic viral polypeptide can be E7.
A visceral double-barreled main body stent graft and methods for its use, the stent graft comprises, a main body stent graft having distal and proximal ends, the main body stent graft's length ranges from about 100-120 mm and diameter at the proximal end ranges from about 30-45 mm, first and second lumens defined at the main body stent graft's distal end, the first lumen's diameter ranges from about 18-20 mm, the second lumen's diameter ranges from about 16-18 mm, the first and second lumens have about the same length from about 50-70 mm, the first lumen is secured to the second lumen along a shared length, and the main body stent graft defines a tubular wall that is contiguous with the first and second lumens such that any fluid entering the main body must exit through one of the first or second lumens.
A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
A61F 2/852 - Two or more distinct overlapping stents
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
A61F 2/856 - Single tubular stent with side portal passage
A61F 2/954 - Instruments specially adapted for placement or removal of stents or stent-grafts for placing stents or stent-grafts in a bifurcation
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A debranching Great vessel stent graft and methods for its use, where the stent graft comprises, a main body stent graft with a first bifurcation defining a first leg and a second leg, the main body stent graft has distal and proximal ends, the main body stent graft has a diameter at the proximal end in the range from about 18 mm to about 28 mm, the first leg and the second leg each have a diameter in the range from about 12 mm to about 18 mm, the distance from the proximal end of the main body to the distal end of the first leg is in the range from about 30 mm to about 50 mm, and the distance from the proximal end of the main body to the distal end of the second leg is in a range from about 50 mm to about 70 mm.
A61F 2/95 - Instruments specially adapted for placement or removal of stents or stent-grafts
A61F 2/852 - Two or more distinct overlapping stents
A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
A61F 2/856 - Single tubular stent with side portal passage
A61F 2/954 - Instruments specially adapted for placement or removal of stents or stent-grafts for placing stents or stent-grafts in a bifurcation
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
